COLPOVITAL
BIOVITAL
Identification
- Active ingredient (INN)
- PROMESTRIENE
- Internal code
- 11 A 005
- Country of Origin
- Algeria
- Pharmaceutical form
- Soft Vaginal Capsule
- Prescription List
- Regulated (List II)
- Packaging
- b/10
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Promestriene (3-propyl ethyl, 17B-methyl estradiol) has been used in trials studying the prevention of Hypospadias.
It is a synthetic estrogen analog, which is used in topical estrogen therapy.
Promestriene's potential for treating vaginal atrophy symptoms associated with aromatase inhibitor treatment would be precluded if its minimal absorption leads to estrogen-like effects on cell proliferation and estrogen-responsive gene expression.
The concern with absorbed vaginal estrogens or estrogen analogs is that they activate occult sites of residual breast cancer or negate the tumor suppressive effects of aromatase inhibitor adjuvant therapy.
Promestriene has been studied in phase
Intravenous of the clinical trial on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security in patients with vaginitis atrophic pelvic; organ prolapse and endometrial hyperplasia.
It has been also studied in phase III of the clinical trial in the post-operative patients with hypospadias.
In addition, promestriene was in phase Intravenous of the clinical trial to study its treatment of patients with vaginosis, bacterial, but that studied was terminated.
Indications
Not Available
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.